These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
480 related articles for article (PubMed ID: 30550613)
1. Δ9-Tetrahydrocannabinol and Cannabidiol Differentially Regulate Intraocular Pressure. Miller S; Daily L; Leishman E; Bradshaw H; Straiker A Invest Ophthalmol Vis Sci; 2018 Dec; 59(15):5904-5911. PubMed ID: 30550613 [TBL] [Abstract][Full Text] [Related]
2. A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice. Long LE; Chesworth R; Huang XF; McGregor IS; Arnold JC; Karl T Int J Neuropsychopharmacol; 2010 Aug; 13(7):861-76. PubMed ID: 19785914 [TBL] [Abstract][Full Text] [Related]
3. A GPR18-based signalling system regulates IOP in murine eye. Caldwell MD; Hu SS; Viswanathan S; Bradshaw H; Kelly ME; Straiker A Br J Pharmacol; 2013 Jun; 169(4):834-43. PubMed ID: 23461720 [TBL] [Abstract][Full Text] [Related]
4. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Pertwee RG Br J Pharmacol; 2008 Jan; 153(2):199-215. PubMed ID: 17828291 [TBL] [Abstract][Full Text] [Related]
5. Cannabinoid receptor expression in non-small cell lung cancer. Effectiveness of tetrahydrocannabinol and cannabidiol inhibiting cell proliferation and epithelial-mesenchymal transition in vitro. Milian L; Mata M; Alcacer J; Oliver M; Sancho-Tello M; Martín de Llano JJ; Camps C; Galbis J; Carretero J; Carda C PLoS One; 2020; 15(2):e0228909. PubMed ID: 32049991 [TBL] [Abstract][Full Text] [Related]
6. Effect of sublingual application of cannabinoids on intraocular pressure: a pilot study. Tomida I; Azuara-Blanco A; House H; Flint M; Pertwee RG; Robson PJ J Glaucoma; 2006 Oct; 15(5):349-53. PubMed ID: 16988594 [TBL] [Abstract][Full Text] [Related]
7. Interaction between delta-9-tetrahydrocannabinol and indomethacin. Green K; Kearse EC; McIntyre OL Ophthalmic Res; 2001; 33(4):217-20. PubMed ID: 11464074 [TBL] [Abstract][Full Text] [Related]
8. Effect of low doses of delta9-tetrahydrocannabinol and cannabidiol on the extinction of cocaine-induced and amphetamine-induced conditioned place preference learning in rats. Parker LA; Burton P; Sorge RE; Yakiwchuk C; Mechoulam R Psychopharmacology (Berl); 2004 Sep; 175(3):360-6. PubMed ID: 15138755 [TBL] [Abstract][Full Text] [Related]
9. A randomised controlled trial of vaporised Δ Solowij N; Broyd S; Greenwood LM; van Hell H; Martelozzo D; Rueb K; Todd J; Liu Z; Galettis P; Martin J; Murray R; Jones A; Michie PT; Croft R Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105 [TBL] [Abstract][Full Text] [Related]
10. Single and combined effects of plant-derived and synthetic cannabinoids on cognition and cannabinoid-associated withdrawal signs in mice. Myers AM; Siegele PB; Foss JD; Tuma RF; Ward SJ Br J Pharmacol; 2019 May; 176(10):1552-1567. PubMed ID: 29338068 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of recombinant human T-type calcium channels by Delta9-tetrahydrocannabinol and cannabidiol. Ross HR; Napier I; Connor M J Biol Chem; 2008 Jun; 283(23):16124-34. PubMed ID: 18390906 [TBL] [Abstract][Full Text] [Related]
12. Toxicological properties of Δ9-tetrahydrocannabinol and cannabidiol. Černe K Arh Hig Rada Toksikol; 2020 Mar; 71(1):1-11. PubMed ID: 32597140 [TBL] [Abstract][Full Text] [Related]
13. Δ Silveira MM; Adams WK; Morena M; Hill MN; Winstanley CA J Psychiatry Neurosci; 2017 Mar; 42(2):131-138. PubMed ID: 28245177 [TBL] [Abstract][Full Text] [Related]
14. Oral efficacy of Δ(9)-tetrahydrocannabinol and cannabidiol in a mouse neuropathic pain model. Mitchell VA; Harley J; Casey SL; Vaughan AC; Winters BL; Vaughan CW Neuropharmacology; 2021 May; 189():108529. PubMed ID: 33741405 [TBL] [Abstract][Full Text] [Related]
15. Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Fusar-Poli P; Crippa JA; Bhattacharyya S; Borgwardt SJ; Allen P; Martin-Santos R; Seal M; Surguladze SA; O'Carrol C; Atakan Z; Zuardi AW; McGuire PK Arch Gen Psychiatry; 2009 Jan; 66(1):95-105. PubMed ID: 19124693 [TBL] [Abstract][Full Text] [Related]
16. Opposite Roles for Cannabidiol and δ-9-Tetrahydrocannabinol in Psychotomimetic Effects of Cannabis Extracts: A Naturalistic Controlled Study. Sainz-Cort A; Jimenez-Garrido D; Muñoz-Marron E; Viejo-Sobera R; Heeroma J; Bouso JC J Clin Psychopharmacol; 2021 Sep-Oct 01; 41(5):561-570. PubMed ID: 34412109 [TBL] [Abstract][Full Text] [Related]
17. Nonpsychotropic cannabinoids, abnormal cannabidiol and canabigerol-dimethyl heptyl, act at novel cannabinoid receptors to reduce intraocular pressure. Szczesniak AM; Maor Y; Robertson H; Hung O; Kelly ME J Ocul Pharmacol Ther; 2011 Oct; 27(5):427-35. PubMed ID: 21770780 [TBL] [Abstract][Full Text] [Related]
18. Activation of CB Joffre J; Yeh CC; Wong E; Thete M; Xu F; Zlatanova I; Lloyd E; Kobzik L; Legrand M; Hellman J J Immunol; 2020 Jun; 204(12):3339-3350. PubMed ID: 32385136 [No Abstract] [Full Text] [Related]
19. Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomised, double-blind, placebo-controlled study in cannabis users. Hindocha C; Freeman TP; Schafer G; Gardener C; Das RK; Morgan CJ; Curran HV Eur Neuropsychopharmacol; 2015 Mar; 25(3):325-34. PubMed ID: 25534187 [TBL] [Abstract][Full Text] [Related]
20. Psychotropic and nonpsychotropic cannabis derivatives inhibit human 5-HT(3A) receptors through a receptor desensitization-dependent mechanism. Xiong W; Koo BN; Morton R; Zhang L Neuroscience; 2011 Jun; 184():28-37. PubMed ID: 21477640 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]